dr-michelle-hermiston-md-104-1440x784-2x
dr-michelle-hermiston-md-104-320x320-2x

Michelle L. Hermiston

MD PhD

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Director, Pediatric Immunotherapy Program
Runner and camper

Dr. Michelle L. Hermiston is a specialist in caring for children with blood diseases, including cancers of the blood. In research, she has a special interest in defining the underlying mechanisms in the development of lymphoid malignancies, including leukemia and lymphoma.

Hermiston earned her medical degree and a doctorate in developmental biology at Washington State University. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at UCSF before joining the faculty in 2002. She also participated in a medical scientist training program at Washington University and in the UCSF Molecular Medicine Research Fellowship Program.

Hermiston is a member of numerous professional organizations, including the American Society of Hematology and American Academy of Pediatrics.

  • Education

    Washington University , MD, 1997

  • Residencies

    UCSF, Pediatrics, 1999

  • Fellowships

    UCS, Pediatric Hematology and Oncology, 2002

  • Academic Title

    Associate Professor

Related conditions

Clinics I work with (3)

blood-and-marrow-transplant-clinic-320x320-2x 3

Blood & Marrow Transplant (BMT) Clinic

Blood & Marrow Transplant (BMT) Clinic

San Francisco / Oakland
hematology-clinic-320x320-2x 5

Hematology Clinic

Hematology Clinic

San Francisco / Oakland / Santa Rosa / Walnut Creek
oncology-clinic-320x320-2x 3

Oncology Clinic

Oncology Clinic

San Francisco / Oakland / Walnut Creek

Where I see patients (3)

    Selected research

    See all research
    Decorative Caduceus

    Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

    DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.

    Recruiting

    More about this study
    Decorative Caduceus

    Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemo...

    The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.

    Recruiting

    More about this study
    Decorative Caduceus

    Epigenetic Reprogramming in Relapse/Refractory AML

    The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy

    Recruiting

    More about this study
    Decorative Caduceus

    Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed...

    MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT), will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4...

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Smell the roses

    Wander outside into our Butterfly Garden in Oakland and our healing gardens at Mission Bay.

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.
    This provider is employed by a medical group affiliated with UCSF.

    Share